We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+2.35%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$7.71B
AUM Growth
-$201M
Cap. Flow
-$473M
Cap. Flow %
-6.14%
Top 10 Hldgs %
39.08%
Holding
169
New
28
Increased
15
Reduced
34
Closed
19

Top Buys

Rank Stock Value
1
NAUT icon
Nautilus Biotechnolgy
NAUT
+$96.5M
2
UTHR icon
United Therapeutics
UTHR
+$84.1M
3
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
+$79.6M
4
ZY
Zymergen Inc. Common Stock
ZY
+$64.5M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$60M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$46.3M
2
ALLO icon
Allogene Therapeutics
ALLO
+$40.4M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$39.9M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$36.4M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$35.4M

Sector Composition

Rank Sector Weight
1 Healthcare 87.76%
2 Miscellaneous 11.22%
3 Financials 0.64%
4 Consumer Staples 0.2%
5 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STOK icon
76
Stoke Therapeutics
STOK
$1.82B
$22.6M 0.29%
671,978
– –
AGRX
77
DELISTED
Agile Therapeutics
AGRX
$21.2M 0.27%
7,960
– –
YARW
78
Yarrow Bioscience
YARW
$68.1M
$20.3M 0.26%
6,416
-1,111
-15% -$4.4M
ONCR
79
DELISTED
Oncorus, Inc.
ONCR
$20.2M 0.26%
1,463,599
-526,388
-26% -$8.13M
CLOV icon
80
Clover Health Investments
CLOV
$2.48B
$20M 0.26%
1,500,000
– –
VRNA
81
DELISTED
Verona Pharma
VRNA
$18.9M 0.25%
2,888,889
– –
DAWN
82
DELISTED
Day One Biopharmaceuticals
DAWN
$17.2M 0.22%
+756,047
New +$15.8M
ONEM
83
DELISTED
1Life Healthcare
ONEM
$17.1M 0.22%
516,044
-3,800
-0.7% -$143K
CMIIU
84
DELISTED
CM Life Sciences II Inc. Unit
CMIIU
$16.8M 0.22%
1,250,000
– –
TDOC icon
85
CALL
Teladoc Health
TDOC
$1.2B
$16.6M 0.22%
+100,000
New +$16.2M
ATXS
86
DELISTED
Astria Therapeutics
ATXS
$16.2M 0.21%
1,281,198
+958,939
+298% +$12.5M
IMCR icon
87
Immunocore
IMCR
$1.64B
$15.6M 0.2%
400,000
– –
PNT
88
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$15.4M 0.2%
1,500,000
– –
NEPT
89
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$15M 0.2%
9,178
– –
ACRS icon
90
Aclaris Therapeutics
ACRS
$814M
$14.9M 0.19%
850,000
+200,000
+31% +$4.54M
HCAQ
91
DELISTED
HealthCor Catalio Acquisition Corp. Class A Ordinary Shares
HCAQ
$14.8M 0.19%
1,500,000
– –
NBTX
92
Nanobiotix
NBTX
$1.79B
$14.6M 0.19%
1,059,800
– –
VRDN icon
93
Viridian Therapeutics
VRDN
$2.47B
$14.5M 0.19%
+794,506
New +$13.6M
ADPT icon
94
Adaptive Biotechnologies
ADPT
$4.26B
$14.4M 0.19%
352,804
– –
VTRS icon
95
Viatris
VTRS
$19.1B
$14.4M 0.19%
1,004,419
– –
FUSN
96
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$14.3M 0.19%
1,775,167
-175,000
-9% -$1.51M
CYPH
97
Cypherpunk Technologies Inc
CYPH
$239M
$13.9M 0.18%
847,650
– –
HRMY icon
98
Harmony Biosciences
HRMY
$2.46B
$13.9M 0.18%
491,332
+179,659
+58% +$5.39M
CMLTU
99
DELISTED
CM Life Sciences III Inc. Unit
CMLTU
$13.7M 0.18%
+1,250,000
New +$13.5M
ACCD
100
DELISTED
Accolade Inc
ACCD
$13.3M 0.17%
245,741
-100,000
-29% -$4.86M
2 3
4
5 6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2021 Portfolio in Review

As of Q2 2021, Perceptive Advisors held 169 positions worth $7.71B, down 2.5% from $7.91B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Perceptive Advisors withdrew a net $473M in Q2 2021, closing 19 positions and reducing 34 holdings. Its most notable exit was Allogene Therapeutics, an estimated $40.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 84% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Perceptive Advisors opened a new position in Nautilus Biotechnolgy worth $90M.

  • Perceptive Advisors's largest Q2 2021 buy was Nautilus Biotechnolgy: 8,911,151 shares worth $90M.
  • Perceptive Advisors added most to United Therapeutics in Q2 2021, an estimated $84.1M increase.
  • Perceptive Advisors's biggest Q2 2021 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $46.3M.
  • Perceptive Advisors fully exited Allogene Therapeutics in Q2 2021, selling an estimated $40.4M.
  • Perceptive Advisors's ten largest holdings make up 39% of its $7.71B portfolio in Q2 2021.
  • Perceptive Advisors opened 28 new positions and closed 19 in Q2 2021.
  • Perceptive Advisors's portfolio value fell 2.5% quarter-over-quarter to $7.71B.

Based on Perceptive Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.